Vulvar and Vaginal Atrophy
📧 Sign up to get email alerts when something new happens for Vulvar and Vaginal Atrophy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Regenerative Treatment of Female Genital Atrophy [Phase 1, Phase 2]
This entry reports the completion of Phase 1/Phase 2 trials evaluating a regenerative treatment for vulvar and vaginal atrophy.
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders [Phase 4]
Phase 4 trial evaluating the effects of ospemifene on brain activation patterns in women with female sexual interest/arousal disorder. The s…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women [Phase 1]
Phase 1 open-label study to evaluate the pharmacokinetics and safety of DARE-HRT1 in healthy postmenopausal women has completed and results …
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy [Phase 3]
A Phase 3 clinical trial comparing Estradiol Vaginal Inserts 4 mcg to IMVEXXY for the treatment of dyspareunia in women with vulvar and vagi…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy [Phase 4]
Phase 4 clinical trial comparing two doses of Estrogel to placebo in postmenopausal symptoms, assessing vasomotor symptoms and vulvar/vagina…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-08-11Clinical Trial Update: Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy [Phase 3]
Phase 3 trial comparing two treatments for vulvar and vaginal atrophy has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-11-21Clinical Trial Update: Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects [NA]
A prospective, open-label, single-center, non-comparative study evaluated the Pixel CO2 Laser System (FemiLift) for vulvar and vaginal atrop…
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women. [Phase 3]
A Phase 3 trial evaluating generic estradiol 10 mcg vaginal tablets for vulvar and vaginal atrophy in postmenopausal women has completed.
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women [Phase 3]
This Phase 3 clinical trial update reports results for estradiol vaginal softgel capsules in treating symptoms of vulvar and vaginal atrophy…
-
CLINICAL_TRIALS trial_result · 2015-12-14Clinical Trial Update: TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy [Phase 2]
Phase 2 trial TXV13-01 assessed estradiol vaginal softgel capsules for postmenopausal vulvar and vaginal atrophy. The study has completed an…
-
CLINICAL_TRIALS trial_result · 2013-09-02Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of Enjuvia 0.3 mg for vulvar and vaginal atrophy due to menopause has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-28Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women [Phase 2]
Phase 2 clinical trial evaluated the efficacy and safety of ospemifene for vulvar and vaginal atrophy in postmenopausal women; results have …
-
CLINICAL_TRIALS trial_result · 2013-06-28Clinical Trial Update: A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women [Phase 3]
This Phase 3 clinical trial evaluated ospemifene for vulvar and vaginal atrophy in postmenopausal women and has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2013-06-28Clinical Trial Update: Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus [Phase 3]
Phase 3 long-term safety study evaluating daily oral ospemifene at 30 mg and 60 mg for vulvar and vaginal atrophy in postmenopausal women wi…
-
CLINICAL_TRIALS trial_result · 2013-06-28Clinical Trial Update: Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus [Phase 3]
Phase 3 long-term safety data for ospemifene 60 mg daily in postmenopausal women with vulvar and vaginal atrophy have been reported, with re…